Location History:
- Kamakura, JP (1997 - 2001)
- Fujisawa, JP (2010)
Company Filing History:
Years Active: 1997-2010
Title: Tetsuo Sudo: Innovator in Hematology and Cell Growth
Introduction
Tetsuo Sudo is a prominent inventor based in Fujisawa, Japan. He has made significant contributions to the field of hematology and cell growth, holding a total of 4 patents. His work focuses on innovative proteins and methods that enhance the growth and differentiation of stem cells.
Latest Patents
One of Tetsuo Sudo's latest patents is related to a protein having an EGF-like repeat sequence. This invention provides a SELF protein that has controlling effects on the growth and differentiation of undifferentiated cells. The patent includes a SELF gene encoding the protein, a recombinant vector, and a transformed cell containing the SELF gene. Additionally, it outlines a method for treatment or prophylaxis using the SELF protein or a recombinant expression vector containing the SELF gene. Another significant patent is for a hemopoietic stem cell multiplier. This invention features a hemopoietic stem cell augmenting agent that contains at least one type of hepatocyte growth factor as an active component. This factor is beneficial for treating bone marrow suppression and malfunctions, as well as for the in vitro growth of peripheral blood stem cells and bone marrow stem cells.
Career Highlights
Tetsuo Sudo is currently associated with Toray Industries, Inc., where he continues to innovate in the field of biotechnology. His work has been instrumental in advancing treatments for various hematological conditions.
Collaborations
Throughout his career, Tetsuo has collaborated with notable colleagues, including Tatsutoshi Nakahata and Genji Kawano. These partnerships have contributed to the development of his groundbreaking inventions.
Conclusion
Tetsuo Sudo's contributions to the field of cell growth and hematology are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science. His work continues to have a significant impact on the treatment of hematological disorders.